Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis

References

• Jemal A, Siegel R, Ward E, et al Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, et al Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431–436.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, et al Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma 2009;50:1096–1101.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544–1552.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, et al Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291–5297.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Zhang L-H, et al Opposing effects of dexamethasone on lenalidomide activity in multiple myeloma: additive/synergistic effects on anti-proliferative activity on myeloma cells and antagonistic effects on immune function. Blood 2008;112(Suppl. 1): 953 (Abstract 2761).
   Google Scholar
• Miguel JFS, Dimopoulos M, Weber D, et al Dexamethasone dose adjustments seem to result in better efficacy and improved tolerability in patients with relapsed/refractory multiple myeloma who are treated with lenalidomide/dexamethasone (MM009/010 sub-analysis). Blood 2007;110(Suppl. 1): 796a (Abstract 2712).
   PubMed Web of Science ®Google Scholar
• Rajkumar S, Jacobus S, Callander N, et al A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2007;110(Suppl. 1): 31a (Abstract 74).
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:4851–4852; author reply 4852–4853.
   PubMed Web of Science ®Google Scholar
• Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(Suppl. 1): I107–I113.
   PubMedGoogle Scholar
• Davies FE, Raje N, Hideshima T, et al Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210–216.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Rogovitz A, Lopez-Girona A, et al Stimulation of T cells by lenalidomide involves putative lenalidomide binding proteins CD3-epsilon-associated protein and GDP-mannose pyrophosphorylase a. Blood 2008;112(Suppl. 1): 903 (Abstract 2606).
   Google Scholar
• Richardson PG, Blood E, Mitsiades CS, et al A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ, et al Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775–779.
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16–19.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Xie W, Mitsiades C, et al Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518–3525.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Gertz MA, Dispenzieri A, et al Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–1184.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Jayabalan DS, Christos PJ, et al BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008;111:1101–1109.
   PubMed Web of Science ®Google Scholar